Hepatic Cell News Volume 4.41 | Oct 30 2020

    By
    Justin.choi
    -
    0
    96







    2020-10-30 | HCN 4.40


    Hepatic Cell News by STEMCELL Technologies
    Vol. 4.40 – 30 October, 2020
    TOP STORY

    Single-Cell Transcriptomics Reveals Early Emergence of Liver Parenchymal and Non-Parenchymal Cell Lineages

    Researchers characterized two distinct mesothelial cell types as well as early hepatic stellate cells and revealed distinct spatiotemporal distributions for these populations.
    [Cell]

    Abstract
    Graphical Abstract


    Learn more about HepatiCult Organoid Growth Medium (Mouse)
    PUBLICATIONSRanked by the impact factor of the journal

    EAG1
    Enhances Hepatocellular Carcinoma Proliferation by Modulating SKP2 and Metastasis through Pseudopod Formation

    Scientists verified that Ether-à-go-go-1 (EAG1) promoted the proliferation of hepatocellular carcinoma both in vitro and in vivo. It promoted cell cycle progression by inhibiting the ubiquitination of SKP2.
    [Oncogene]

    Abstract

    TRIM25
    Promotes Capicua Degradation Independently of ERK in the Absence of ATXN1L

    Functional in vitro studies utilizing ATXN1LKO human cell lines revealed that loss of ATXN1L led to the accumulation of polyubiquitinated Capicua protein, promoting its degradation through the proteasome.
    [BMC Biology]

    Full Article

    Indole
    Hydrazide Compound ZJQ-24 Inhibits Angiogenesis and Induces Apoptosis Cell Death through Abrogation of AKT/mTOR Pathway in Hepatocellular Carcinoma

    MTT assays, flow cytometric analysis, Western blotting and immunohistochemistry identified that ZJQ-24 effectively suppressed hepatocellular carcinoma cell proliferation via G2/M phase arrest and caspase-dependent apoptosis but had no cytotoxic on normal cells.
    [Cell Death & Disease]

    Full Article

    microRNA-199a-3p
    Inhibits Hepatic Apoptosis and Hepatocarcinogenesis by Targeting PDCD4

    In an acetaminophen-induced acute hepatic injury model, hepatocyte-specific miR-199a-3p knockout aggravated hepatic apoptosis.
    [Oncogenesis]

    Full Article

    β-Arrestin2
    Deficiency Attenuates Oxidative Stress in Mouse Hepatic Fibrosis through Modulation of NOX4

    Hepatic fibrosis is a disease characterized by excessive deposition of ECM in the liver. The authors investigated whether β-arrestin2 regulated oxidative stress in hepatic fibrosis.
    [Acta Pharmacologica Sinica]

    Abstract

    Primary Human Hepatocytes Spheroid Model as a 3D In Vitro
    Platform for Metabolism Studies

    The 3D primary human hepatocytes spheroid model showed promise to be used in drug discovery projects to study drug metabolism, including unknown mechanisms, over an extended period of time.
    [Journal of Pharmaceutical Sciences]

    AbstractFull Article


    Pathogen infection studies lacked an optimal culture system. Then she used organoids.
    REVIEWS

    The
    Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma

    The authors summarize rapidly emerging clinical data on the promise and challenges of implementing immune checkpoint cascades in hepatocellular carcinoma and discuss the unmet need of biomarkers to predict response or resistance to therapy.
    [JAMA Oncology]

    Abstract

    Antigen
    Presentation, Autoantibody Production, and Therapeutic Targets in Autoimmune Liver Disease

    Investigators summarize emerging aspects of antigen presentation, autoantibody production, and the application of novel therapeutic approaches in the characterization and treatment of autoimmune liver diseases.
    [Cellular & Molecular Immunology]

    Full Article

    INDUSTRY AND POLICY NEWS

    Aligos
    Therapeutics Doses First Subject in Phase I Proof-of-Concept Study of Small Molecule Drug Candidate ALG-000184 for Chronic Hepatitis B

    Aligos Therapeutics, Inc. announced that it has dosed its first subject in a first-in-human Phase Ia/b clinical trial, ALG-000184-201. The study will evaluate ALG-000184, a small molecule class II capsid assembly modulator that targets hepatitis B virus capsid assembly as well as the establishment of covalently closed circular DNA.
    [Aligos Therapeutics, Inc.]

    Press Release

    European
    Patent Office Rules in Favor of Sanofi and Regeneron Concerning Praluent® (Alirocumab)

    The European Patent Office Technical Boards of Appeal has ruled in Sanofi and Regeneron’s favor, invalidating certain claims of Amgen’s European patent directed to PCSK9 antibodies relevant to Praluent®. Praluent will continue to be available in European countries where it is approved for use and for sale.
    [Sanofi]

    Press Release

    FEATURED EVENT

    Keystone
    Symposia: Fatty Liver Disease and Multi-System Complications

    March 22 – March 24, 2021
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Bioinformatician – Metabolic and Cardiovascular Diseases

    Pfizer – Cambridge, Massachusetts

    Statistical
    Geneticist – Disorders of the Liver, Eye and Nervous System

    Deep Genomics, Inc. – Toronto, Ontario, Canada

    Postdoctoral Positions – Stem Cells, Immunology, Biochemistry/Molecular Biology, Pathogenic Microbiology

    Zhejiang University-University of Edinburgh Institute – Haining, Zhejiang, China

    Postdoctoral Positions – Translational Oncology

    Medical University of Vienna – Vienna, Austria

    Faculty Position – Cancer Biology

    University of Texas Southwestern Medical Center – Dallas, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Hepatic Cell News
    Archives Contact Us
    Hepatic Cell News Twitter